Frequency Therapeutics

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The firm's progenitor cell activation approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. Its product pipeline include Sensorineural hearing loss (FX-322), and Multiple Sclerosis. The company was founded by Robert S. Langer, Jr., David L. Lucchino, Christopher Loose and Will J. McLean on November 13, 2014 and is headquartered in Woburn, MA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Korro Bio, Inc. is an RNA editing company, which engages in the discovery and development of genetic medicines. The company was founded by Nessan Bermingham, Jean-Francois Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

NEW YORK--(BUSINESS WIRE)-- #Frequency--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of investors that purchased Frequency Therapeutics, Inc. (NASDAQ:FREQ) securities between November 16, 2020 and March 22, 2021, both dates inclusive (the “Class Period”). Investors have until August 2, 2021 to apply to the Court to be appointed as lead

FREQUENCY THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Frequency Therapeutics, Inc. and Encourages Investors to Contact the Firm

SAN DIEGO & WOBURN, Mass.--(BUSINESS WIRE)---- $FREQ #ClassAction--Shareholder rights law firm Robbins LLP announces that a class action has been filed on behalf of all purchasers of Frequency Therapeutics, Inc. (NASDAQ: FREQ) securities between November 16, 2020 and March 22, 2021, against the Company for remedies under the Securities Exchange Act of 1934. Frequency Therapeutics is a pharmaceutical company that develops and commercializes a hearing loss treatment called "FX-322" for patients with severe sensorineura

SHAREHOLDER ALERT: Robbins LLP Announces that Frequency Therapeutics, Inc. (FREQ) is Being Sued for Misleading Shareholders

SAN DIEGO--(BUSINESS WIRE)-- #FREQstock--Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the District of Massachusetts on behalf of purchasers of Frequency Therapeutics, Inc. (NASDAQ: FREQ) common stock between November 16, 2020 and March 22, 2021, inclusive (the “Class Period”). The case is captioned Evans v. Frequency Therapeutics, Inc., No. 21-cv-10933, and is assigned to Judge William G. Young. The Frequency Therapeutics class action lawsuit charges Frequency

Notice of Lead Plaintiff Deadline for Shareholders in the Frequency Therapeutics, Inc. Class Action Lawsuit

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Frequency Therapeutics, Inc. (NASDAQ: FREQ) between November 16, 2020 and March 22, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 2, 2021. SO WHAT: If you purchased Frequency securities during the Cla

FREQ BREAKING ALERT: Rosen Law Firm Encourages Frequency Therapeutics, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline – FREQ

NEW YORK--(BUSINESS WIRE)-- #FREQ--INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Frequency, Inc. (NASDAQ: FREQ)

INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Frequency, Inc. (NASDAQ: FREQ)

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present at two upcoming investor conferences: Jefferies Virtual Healthcare Conference on June 2, 2021 at 2:30 p.m. EDT Goldman Sachs 42nd Annual Global Healthcare Conference on June 10,

Frequency Therapeutics to Present at Upcoming Jefferies and Goldman Sachs Healthcare Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc., (Nasdaq: FREQ) today shared a statement from David L. Lucchino, Frequency's Chief Executive Officer, in support of the Hearing Loss Association of America (HLAA) and its efforts to advance the voice of the patient in leading the first-ever Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting on sensorineural hearing loss (SNHL). Patient-Focused Drug Development meetings are designed to provide the U.S. Food and Drug A

Frequency Therapeutics Provides Statement of Support for the Hearing Loss Association of America's Externally-Led Patient-Focused Drug Development Meeting to Address Sensorineural Hearing Loss

NEW YORK--(BUSINESS WIRE)-- #FREQ--Scott+Scott Attorneys at Law LLP Announces Investigation into Frequency Therapeutics, Inc. (FREQ)

Scott+Scott Attorneys at Law LLP Announces Investigation into Frequency Therapeutics, Inc. (FREQ)

Frequency Therapeutics, Inc. (FREQ) delivered earnings and revenue surprises of -122.22% and -41.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Frequency Therapeutics, Inc. (FREQ) Reports Q1 Loss, Misses Revenue Estimates

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced business updates and financial results for the first quarter ended March 31, 2021. “As we work to develop a novel medicine for the treatment of the most common form of hearing loss, our initial focus has been to investigate the broadest s

Frequency Therapeutics Provides Business Updates and Reports First Quarter 2021 Financial Results

Axsome Therapeutics

Trillium Therapeutics

Their stocks have collapsed. But they could still be huge winners.

3 Biotech Stocks That Could Be Millionaire-Makers

I previously covered Frequency Therapeutics after the company had initiated a Phase 2a trial on the heels of a positive Phase 1/2 trial. This Phase 2a trial featured about three times more patients but failed to show the same promising efficacy in a recent data read-out.

Frequency Therapeutics: A Look At What's Next After A Disappointing Data Readout

A risky path lies ahead for the clinical-stage biotech, which saw disappointing results for FX-322 in March 2021. Can management learn from its mistakes?

Are Disappointing Results an Opportunity for Frequency Therapeutics Investors?

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the expansion of its clinical development team with the addition of Jeffery T. Lichtenhan, Ph.D., a leading expert in hearing diagnostics and measurement. Dr. Lichtenhan, an auditory neuroscientist, will help to advance the Company's hear

Frequency Therapeutics Expands its Clinical Development Team, Adding Expertise in Inner Ear Physiology and Translational Science

Solid Biosciences

Scholar Rock Holding Corp

These drugmaker stocks may have been hammered down to bargain-bin prices.

3 Beaten-Down Biotech Stocks: Can They Recover?

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present a company overview at the 20th Annual Needham Virtual Healthcare Conference. Mr. Lucchino's presentation will take place on Wednesday, April 14 at 8:00 a.m. EDT. A live webcast of t

Frequency Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

NEW YORK, April 6, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Frequency Therapeutics, Inc. ("Frequency" or the "Company") (NASDAQ: FREQ). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Frequency Therapeutics, Inc. - FREQ

LOS ANGELES, April 2, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ: FREQ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Frequency Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $FREQ #FREQ--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Frequency Therapeutics, Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Frequency Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $FREQ #FREQ--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Frequency Therapeutics, Inc.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Frequency Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

Frequency Therapeutics, Inc. (FREQ) delivered earnings and revenue surprises of 0.00% and -2.93%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Frequency Therapeutics, Inc. (FREQ) Reports Q4 Loss, Lags Revenue Estimates

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced business updates and financial results for the fourth quarter and year ended December 31, 2020. “We recently obtained valuable data from two clinical studies in patients with sensorineural hearing loss that have provided us with important le

Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2020 Financial Results

Frequency Therapeutics Inc. (NASDAQ: FREQ) shares were absolutely crushed in Tuesday's session.

Is the Frequency Therapeutics Recovery a Dead Cat Bounce?

The stock price of Frequency Therapeutics Inc (NASDAQ: FREQ) has increased by over 10% pre-market. This is why it happened.

FREQ Stock Price Increases Over 10% Pre-Market: Why It Happened

Frequency Therapeutics Inc. (NASDAQ: FREQ) stock imploded Tuesday amid the company's announcement that its interim FX-322 Phase 2a results showed that four weekly injections did not demonstrate improvements in hearing measures versus a placebo. The stock was down 76.81% at $8.42 at last check.

News for Frequency Therapeutics Stock (FREQ)